In the melanoma mouse model, the administration of SG7 for two weeks at 10 mg/kg can effectively inhibit the tumor growth; further, SG7 combined with anti-PD1 in the MC38 colon carcinoma model, also obtained similar results, which is a good sign for clinical application [69]. Here, PDCD1 is linked to neoplasm.